Table 2:
Characteristics | Responders (N=11) | Non-Responders (N=26) | P Value |
---|---|---|---|
Age (years) | 65 [50–75] | 63 [25–75] | 0.47 |
Male | 6 (55) | 13 (50) | >0.99 |
Secondary AML | 2 (18) | 7 (27) | 0.69 |
AML status | 0.27 | ||
Primary refractory | 2 (18) | 10 (38) | |
Relapsed | 9 (82) | 16 (62) | |
Prior regimens | 2 [1–3] | 2 [1–6] | 0.11 |
Int/High dose cytarabine-based | 7 (64) | 19 (73) | 0.69 |
HMA | 5 (45) | 16 (62) | 0.47 |
Clofarabine-based | 3 (27) | 7 (27) | >0.99 |
Prior SCT | 1 (9) | 8 (31) | 0.22 |
WBC (x106 /L) | 1.5 [1–5.6] | 1.8 [0.4–7.7] | 0.76 |
Hemoglobin (g/dL) | 9.7 [7.4–13.6] | 9.5 [7.7–14.6] | 0.85 |
Platelets (x109/L) | 34 [6–231] | 25 [2–148] | 0.03 |
Bone marrow blasts (%) | 16 [7–68] | 37.5 [3–95] | 0.009 |
Peripheral blasts (%) | 0 [0–41] | 23 [0–84] | 0.01 |
Cytogenetics | |||
Diploid | 10 (91) | 8 (31) | 0.001 |
Complex | 0 | 12 (46) | 0.006 |
−5/5q- and/or −7/7q- | 0 | 12 (46) | 0.006 |
AML: acute myeloid leukemia; Int: Intermediate; HMA: hypomethylating agents; SCT: stem cell transplantation; WBC: white blood cell count.